Chengbin Wu
Company: Epimab Biotherapeutics
Job title: Chief Executive Officer
Seminars:
From Antibody Engineering to Clinical Development in EMB-06 – A BCMA/ CD3 Targeting BiTE 3:15 pm
Exploring antibody engineering for EMB-06 Delving into the shift from oncology to autoimmune indication – targeting both multiple myeloma and autoimmune diseases Looking into phase 1 trial results for EMB-06 and next stepsRead more
day: Day 1